Pharming To Acquire Abliva And Mitochondrial Disease ‘Potential Blockbuster’ Asset

Looking to diversify in the face of competition to its main earner, Ruconest, the Netherlands-based Pharming may have bagged itself a rare disease bargain with Abliva.